863578-19-2Relevant articles and documents
Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase
Stansfield, Ian,Ercolani, Caterina,Mackay, Angela,Conte, Immacolata,Pompei, Marco,Koch, Uwe,Gennari, Nadia,Giuliano, Claudio,Rowley, Michael,Narjes, Frank
scheme or table, p. 627 - 632 (2009/09/06)
We report the evolutionary path from an open-chain series to conformationally constrained tetracyclic indole inhibitors of HCV NS5B-polymerase, where the C2 aromatic is tethered to the indole nitrogen. SAR studies led to the discovery of zwitterionic comp
PENTACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS
-
Page/Page column 29, (2008/06/13)
The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R1, R2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR
-
Example 1-1, (2008/06/13)
The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.